FDA Advances Real-Time Clinical Trials Implementation
Decision brief
Answer first · skim in under a minute
The FDA has made notable strides in implementing real-time clinical trials, a development that could reshape the pharmaceutical landscape. This article explores the implications for business development teams and investors.
The U.S. Food and Drug Administration is advancing real-time clinical trials (RTCT), announcing on April 28, 2026, that AstraZeneca and Amgen have started proof-of-concept studies that stream endpoints and safety signals to the agency while a broader summer pilot takes shape through a public Request for Information.
Contents10 sections
Key Takeaways
- FDA’s April 28, 2026, announcement confirmed two RTCT proofs-of-concept and an RFI for a wider pilot.
- AstraZeneca’s Phase 2 TRAVERSE mantle cell lymphoma trial has already delivered validated real-time signals via Paradigm Health.
- Amgen’s Phase 1b STREAM-SCLC study in limited-stage small cell lung carcinoma is underway, with final site selection still open.
- FDA planned pilot selection criteria in July 2026 and participant selections in August 2026 after the RFI comment window.
What progress has FDA made on real-time clinical trials?
According to the FDA press announcement, the agency framed early-phase trials as a development bottleneck where data usually move from sites to sponsors before regulators see analyses. RTCT aims to let FDA scientists view safety signals and endpoints as trials progress.
Commissioner Marty Makary said traditional lag can delay decisions and slow development, while Chief AI Officer Jeremy Walsh said the proofs-of-concept show real-time sharing is feasible and potentially transformative for patients waiting on therapies.
Which proof-of-concept trials are streaming signals?
FDA named two sponsor programs. AstraZeneca is running a Phase 2 multi-site TRAVERSE study in treatment-naïve mantle cell lymphoma with participation from MD Anderson Cancer Center and the University of Pennsylvania. The registry listing for the chemotherapy-free acalabrutinib–venetoclax–rituximab regimen is NCT05951959 (TrAVeRse) on ClinicalTrials.gov.
Amgen is conducting Phase 1b STREAM-SCLC in limited-stage small cell lung carcinoma; FDA said final site selection was still in process at announcement. For each study, FDA met sponsors to set real-time reporting criteria. The agency said it had already received and validated signals from AstraZeneca’s trial through Paradigm Health, establishing technical feasibility.
What does the Federal Register RFI ask industry?
On April 29, 2026, FDA published an RFI titled “AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program” under Docket FDA-2026-N-4390 in the Federal Register (FR Doc. 2026-08281). The notice seeks input on how AI-enabled technologies could improve efficiency, speed, and decision quality in early-phase trials while preserving regulatory standards.
The original comment deadline was May 29, 2026. FDA later noted an extension to June 29, 2026. The press release said the agency intended to issue final selection criteria in July and complete pilot selections in August.
How could continuous trials change development pacing?
FDA argues most development still runs in discrete phases with protocol-defined pauses between studies. Because RTCT lets the agency see key insights continuously, those hiatuses could shrink, enabling more continuous programs across phases. That ambition remains aspirational until the broader pilot defines metrics, trustworthiness checks, and data-integrity controls.
For European sponsors filing U.S. INDs, the pilot matters even when primary EU oversight stays with EMA/CTIS: early go/no-go, dose selection, and safety surveillance decisions often hinge on FDA interactions for global packages.
What should BD and clinical operations teams watch?
Teams should map whether upcoming Phase 1/2 oncology protocols can support agreed real-time signal definitions without exposing full patient-level datasets beyond FDA’s stated framework. Vendors that already intermediate streaming signals—as Paradigm Health did for TRAVERSE—may become part of inspection-ready data-flow diagrams.
Investors and portfolio leads should treat RTCT as infrastructure progress, not efficacy readout: FDA has not published TRAVERSE or STREAM-SCLC outcome results in the April 28 announcement. The sourced facts are program launch, sponsor names, indication settings, NCT05951959 for TrAVeRse, RFI docket timing, and the July/August 2026 pilot timeline.
What remains unproven?
No FDA document in this package quantifies months saved per program, approval-rate lifts, or AI false-positive rates for streamed signals. Claims inventing those figures are omitted. STREAM-SCLC’s final site list and any public NCT mapping beyond the FDA naming were not confirmed in the primary announcement and are not asserted here.
Related NovaPharma coverage
- FDA Extends Comment Period for Real-Time Clinical Trials AI Pilot
- Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
- Why Europe Must Boost Clinical Trials for Future Growth
Frequently Asked Questions
What did FDA announce on real-time clinical trials in April 2026?
On April 28, 2026, FDA announced proof-of-concept real-time clinical trials (RTCT) with AstraZeneca and Amgen and issued a Request for Information on a broader RTCT pilot planned for summer 2026.
Which proof-of-concept trials are in the RTCT initiative?
AstraZeneca’s Phase 2 TRAVERSE study in treatment-naïve mantle cell lymphoma (NCT05951959) and Amgen’s Phase 1b STREAM-SCLC study in limited-stage small cell lung carcinoma, with final site selection still in process for STREAM-SCLC.
When were RFI comments due for the RTCT pilot?
The April 29, 2026, Federal Register RFI originally set comments for May 29, 2026; FDA later extended the comment period to June 29, 2026.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
